Technology area: Biotechnology & Pharmaceuticals
33 pending office actions • 22 clients • 33 examiners • 27 art units • 0 of 33 (0%) have an AI response strategy ready • 36 patents granted in the last 365 days
DANN, DORFMAN, HERRELL & SKILLMAN has 32 pending office actions in Biotechnology & Pharmaceuticals and 4413 career applications. The firm has a substantial historical application record and a significant number of matters currently requiring examination attention.
The resolved allowance rate is 76.28%, and the average is 3.46 office actions per allowance. The available outcomes show that a majority of resolved cases reach allowance, while successful cases commonly require multiple Office actions.
These figures make prosecution process an important consideration for clients. The application volume indicates broad experience, but the allowance rate and action average suggest that applicants should plan for substantive examination work and evaluate strategy at the individual application level.
Based on the USPTO statutory response window for each pending office action. 14 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 14 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (3%) |
| §103 only | 12 (36%) |
| §112 only | 2 (6%) |
| Double-patenting + other | 3 (9%) |
| Multi-statute (no §101) | 15 (45%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NEGRON, ISMAEL | 1 | 73.6% | +15.1% |
| DAVIS, BRIAN J | 1 | 84.8% | -3.9% |
| SHELTON, SYNPHANE LA'SHAWN | 1 | 100.0% | +0.0% |
| FIORELLO, BENJAMIN F | 1 | 73.9% | +7.5% |
| GEMBEH, SHIRLEY V | 1 | 63.1% | +33.8% |
| PATEL, DEVANG R | 1 | 65.6% | +39.0% |
| WECKER, JENNIFER | 1 | 70.9% | +36.6% |
| PACKARD, BENJAMIN J | 1 | 66.9% | +15.3% |
| PONCIANO, PATRICK BERNAS | 1 | 56.3% | +9.4% |
| ALLEY, GENEVIEVE S | 1 | 60.5% | +48.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17783365 | HIGH-THROUGHPUT DETECTION METHOD FOR RARE MUTATION OF GENE | TURPIN, ZACHARY MARK | 49d overdue |
| 18033627 | COMPOSITIONS AND METHODS FOR IN VIVO GENE TRANSFER | SHIN, DANA H | 37d overdue |
| 18600263 | NANOFIBER AND MICROFIBER HYBRID AEROGELS | ALLEY, GENEVIEVE S | 17d overdue |
| 17786147 | COMPOSITIONS AND METHODS FOR HEMOGLOBIN PRODUCTION | PERSONS, JENNA L | 16d overdue |
| 18856824 | Tunnel Lining Method and Apparatus | FIORELLO, BENJAMIN F | 57d |
| 17461413 | REAL-TIME RAIL WEAR AND DEFECT MONITORING SYSTEM EMPLOYING DISTANCE MEASURING DEVICES | RICHTER, KARA | 69d |
| 19400821 | HAND HOLDABLE LIGHT AND BATTERY HAVING SYMMETRICAL CONTACTS | NEGRON, ISMAEL | — |
| 18987189 | GROWTH FACTOR LOADED NANOFIBERS AND METHODS OF USE THEREOF | DAVIS, BRIAN J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18600263 | NANOFIBER AND MICROFIBER HYBRID AEROGELS | ALLEY, GENEVIEVE S | 17d overdue |
| 18699799 | REFILLABLE TISSUE ENGINEERED SCAFFOLDS | PACKARD, BENJAMIN J | 10d overdue |
| 19400821 | HAND HOLDABLE LIGHT AND BATTERY HAVING SYMMETRICAL CONTACTS | NEGRON, ISMAEL | — |
| 18846364 | METFORMIN NANOFORMULATIONS AND METHODS OF USE THEREOF | GEMBEH, SHIRLEY V | — |
| 18811972 | Alloy for Mud Motor Shaft Applications with High Strength, High Impact Toughness and Excellent Fatigue Life | PATEL, DEVANG R | — |
| 18750367 | COMPOSITIONS AND METHODS FOR THE DETECTION OF BRAIN INJURY | WECKER, JENNIFER | — |
| Art Unit | Apps |
|---|---|
| 1617 | 2 |
| 1611 | 2 |
| 1635 | 2 |
| 1658 | 2 |
| 1656 | 2 |
| 2875 | 1 |
| 1614 | 1 |
| 1652 | 1 |
| 3678 | 1 |
| 1615 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19400821 | HAND HOLDABLE LIGHT AND BATTERY HAVING SYMMETRICAL CONTACTS | Streamlight, Inc. | NEGRON, ISMAEL | 2875 | §102§103§112 | Non-Final OA | — | Pending | Nov 25, 2025 |
| 18987189 | GROWTH FACTOR LOADED NANOFIBERS AND METHODS OF USE THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | DAVIS, BRIAN J | 1614 | §102§103§112 | Non-Final OA | — | Pending | Dec 19, 2024 |
| 18859447 | THYMIDINE KINASE AS A MARKER FOR IMMUNE CHECKPOINT INHIBITOR EFFICACY | Biovica International AB | SHELTON, SYNPHANE LA'SHAWN | 1652 | §103§112 | Non-Final OA | — | Pending | Oct 23, 2024 |
| 18856824 | Tunnel Lining Method and Apparatus | Colin Eddie Consulting Limited | FIORELLO, BENJAMIN F | 3678 | §102§103 | Non-Final OA | 57d | Pending | Oct 14, 2024 |
| 18846364 | METFORMIN NANOFORMULATIONS AND METHODS OF USE THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | GEMBEH, SHIRLEY V | 1615 | §102§103 | Non-Final OA | — | Pending | Sep 12, 2024 |
| 18811972 | Alloy for Mud Motor Shaft Applications with High Strength, High Impact Toughness and Excellent Fatigue Life | Crs Holdings, LLC | PATEL, DEVANG R | 1735 | §103§112 | Non-Final OA | — | Pending | Aug 22, 2024 |
| 18750367 | COMPOSITIONS AND METHODS FOR THE DETECTION OF BRAIN INJURY | Monell Chemical Senses Center | WECKER, JENNIFER | §102§103 | Non-Final OA | — | Pending | Jun 21, 2024 | |
| 18699799 | REFILLABLE TISSUE ENGINEERED SCAFFOLDS | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | PACKARD, BENJAMIN J | 1612 | §103 | Non-Final OA | 10d overdue | Pending | Apr 09, 2024 |
| 18696443 | Improved Sliding Door | Cavity Sliders Limited | PONCIANO, PATRICK BERNAS | 3634 | §103 | Non-Final OA | — | Pending | Mar 28, 2024 |
| 18600263 | NANOFIBER AND MICROFIBER HYBRID AEROGELS | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | ALLEY, GENEVIEVE S | 1617 | §102§103§112 | Final Rejection | 17d overdue | Pending | Mar 08, 2024 |
| 18681728 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS | Cornell University | SHIAO, YIH-HORNG | 1691 | §102§103§112 | Non-Final OA | — | Pending | Feb 06, 2024 |
| 18409324 | DRIVER CIRCUIT AND METHOD FOR A SEMICONDUCTOR LASER | Streamlight, Inc. | CAMACHO ALANIS, FERNANDA ADRIANA | 2828 | §112 | Non-Final OA | — | Pending | Jan 10, 2024 |
| 18510115 | METHODS AND COMPOSITIONS FOR PERTUSSIS DIAGNOSIS | Dx Discovery Inc. | ESSEX, LAURA ANN | 1675 | §112DP | Non-Final OA | — | Pending | Nov 15, 2023 |
| 18287762 | CYCLOSPORINE COMPOSITIONS AND METHODS OF USE THEREOF | Protransit Nanotherapy LLC | HOERNER, PAUL ELLSWORTH | 1611 | §103 | Final Rejection | 87d overdue | Pending | Oct 20, 2023 |
| 18550828 | LIPID NANOPARTICLE FORMULATIONS AND METHODS OF USE THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | RYAN, DOUGLAS CHARLES | 1635 | §103Other | Final Rejection | — | Pending | Sep 15, 2023 |
| 18278865 | Antimicrobial Peptides | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | JAUHARI, SACHI | 1654 | §103Other | Non-Final OA | — | Pending | Aug 25, 2023 |
| 18253121 | Marine Vessel Fender and Control System | C W F Hamilton & Co. Limited | PANDE, ASHUTOSH | 3668 | §103§112 | Final Rejection | — | Pending | May 16, 2023 |
| 18033627 | COMPOSITIONS AND METHODS FOR IN VIVO GENE TRANSFER | The Children's Hospital of Philadelphia | SHIN, DANA H | 1635 | §102§112 | Final Rejection | 37d overdue | Pending | Apr 25, 2023 |
| 18031727 | NOVEL BIOACTIVE PEPTIDE COMBINATIONS AND USES THEREOF | Colzyx AB | KOMATSU, LI N | 1658 | §101§103§112Other | Final Rejection | — | Pending | Apr 13, 2023 |
| 18246572 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HAIR LOSS AND OTHER CONDITIONS | Protransit Nanotherapy LLC | VARADARAJ, ARCHANA | 1658 | §103DP | Final Rejection | 4d overdue | Pending | Mar 24, 2023 |
| 18176546 | Compositions and Methods for Modulating Factor IX Function | The Children's Hospital of Philadelphia | TSAY, MARSHA M | 1656 | §103 | Non-Final OA | 73d overdue | Pending | Mar 01, 2023 |
| 18021956 | AMMONOLYSIS SOLUTION AND AMMONOLYSIS METHOD | Genewiz Inc., Sz | LEE, HOI YAN NMN | 1693 | §103 | Non-Final OA | 63d | Pending | Feb 17, 2023 |
| 17905407 | CRISPR/CAS9 SYSTEM FOR MULTISTRAIN HIV-1 TREATMENT | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | VIVLEMORE, TRACY ANN | 1638 | §103 | Non-Final OA | 28d | Pending | Aug 31, 2022 |
| 17795604 | COMPOSITIONS AND METHODS FOR COATING BONE GRAFTS | UNIVERSITY OF ROCHESTER | BOECKELMAN, JACOB A | 1655 | §103 | Non-Final OA | — | Pending | Jul 27, 2022 |
| 17786147 | COMPOSITIONS AND METHODS FOR HEMOGLOBIN PRODUCTION | The Trustees of the University of Pennsylvania | PERSONS, JENNA L | 1637 | §103§112 | Non-Final OA | 16d overdue | Pending | Jun 16, 2022 |
| 17783365 | HIGH-THROUGHPUT DETECTION METHOD FOR RARE MUTATION OF GENE | Suzhou Smk Gene Tech Ltd. | TURPIN, ZACHARY MARK | 1682 | §103§112 | Non-Final OA | 49d overdue | Pending | Jun 08, 2022 |
| 17777245 | COMPOSITIONS AND METHODS FOR MODULATING FACTOR VIII FUNCTION | The Children's Hospital of Philadelphia | MCKNIGHT, CIARA A | 1656 | §103DP | Non-Final OA | — | Pending | May 16, 2022 |
| 17694841 | Viral Vectors for Prophylaxis and Therapy of Hemoglobinopathies | The Children's Hospital of Philadelphia | MARVICH, MARIA | 1634 | §112 | Non-Final OA | — | Pending | Mar 15, 2022 |
| 17621927 | COMPOSITIONS AND METHODS FOR ENHANCING PLANT GROWTH | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. | PALLAY, MICHAEL B | 1617 | §102§103 | Final Rejection | — | Pending | Dec 22, 2021 |
| 17532123 | COMPOSITIONS AND METHODS FOR HEMOGLOBIN PRODUCTION | Cold Spring Harbor Laboratory | IANNUZO, NATALIE NMN | 1653 | §103 | Non-Final OA | — | Pending | Nov 22, 2021 |
| 17461413 | REAL-TIME RAIL WEAR AND DEFECT MONITORING SYSTEM EMPLOYING DISTANCE MEASURING DEVICES | Avante International Technology, Inc. | RICHTER, KARA | 3645 | §103§112 | Non-Final OA | 69d | Pending | Aug 30, 2021 |
| 17425130 | WHOLE CELL TUMOR VACCINES AND METHODS OF USE THEROF | Children'S National Medical Center | MIDDLETON, DANAYA L | 1674 | §103 | Final Rejection | 28d | Pending | Jul 22, 2021 |
| 16972727 | METHOD FOR PREPARING COMPOSITION COMPRISING KILLED OR INACTIVATED METHANOBREVIBACTER ARCHAEBACTERIA CELLS AND COMPOSITION THEREBY OBTAINED | Duncan-Bruce Sutherland | ALAM, AYAAN A | 1611 | §103 | Final Rejection | 70d | Pending | Dec 07, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial76.3% of resolved applications prosecuted by Dann, Dorfman, Herrell & Skillman were allowed, across 4,413 applications in USPTO records.
3.46 office actions per allowed application on average.
33 pending office actions as of October 2026, for 22 clients, before 33 examiners in 27 art units.
